Abstract:Several APOBEC3 enzymes restrict HIV-1 replication by deaminating cytosine to form uracil in single-stranded proviral (-)DNA. However, HIV-1 Vif binds to APOBEC3 enzymes and counteracts their activity by inducing their proteosomal degradation. This counteraction by Vif is not complete as evidenced by footprints of APOBEC3-mediated mutations within integrated proviral genomes of people living with HIV-1. The APOBEC3 enzymes are co-ordinately expressed in CD4 T cells and relative contributions of APOBEC3s in HIV-1 restriction is not fully understood. In this study, we investigated the activity of co-expressed APOBEC3F and APOBEC3G against HIV-1 Subtype B and Subtype C Transmitted/Founder viruses. APOBEC3F and APOBEC3G when co-expressed were previously determined to form a hetero-oligomer that enables partial resistance of APOBEC3F to Vif-mediated degradation. Here, we determined that that APOBEC3F interacts with APOBEC3G through its N-terminal domain. We provide evidence that this results in protection from Vif-mediated degradation because the APOBEC3F N-terminal domain contains residues required for recognition by Vif. We also found subtype specific differences in activity of Transmitted/Founder Vifs against APOBEC3G and the APOBEC3F/APOBEC3G hetero-oligomer. HIV-1 Subtype C Vifs were more active in counteracting APOBEC3G compared to HIV-1 Subtype B Vifs when APOBEC3G was expressed alone. However, HIV-1 Subtype C Vifs were less active against APOBEC3G when APOBEC3F and APOBEC3G were co-expressed. Consequently, when APOBEC3F and APOBEC3G were expressed together HIV-1 Subtype C viruses showed a decrease in relative infectivity compared to that when APOBEC3G was expressed alone. Inspection of Vif amino acid sequences revealed that that differences in amino acids adjacent to conserved sequences influenced the Vif-mediated APOBEC3 degradation ability. Altogether, the data provide a possible mechanism for how combined expression of APOBEC3F and APOBEC3G could contribute to mutagenesis of HIV-1 proviral genomes in the presence of Vif and provide evidence for variability in the Vif-mediated degradation ability of Transmitted/Founder viruses.

Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia

USP49 Potently Stabilizes APOBEC3G Protein by Removing Ubiquitin and Inhibits HIV-1 Replication

Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies

<i>APOBEC3B</i>Deletion and Risk of HIV‐1 Acquisition

APOBEC proteins and intrinsic resistance to HIV-1 infection

Variability in HIV-1 Transmitted/Founder Virus Susceptibility to Combined APOBEC3F and APOBEC3G Host Restriction

A Naturally Occurring Vif Mutant (I107T) Attenuates Anti-Apobec3g Activity and HIV-1 Replication.

A Single Amino Acid Difference in Human APOBEC3H Variants Determines HIV-1 Vif Sensitivity

Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression.

Reduced Apobec3h Variant Anti-Viral Activities Are Associated With Altered Rna Binding Activities

Lack of Association between Intact/Deletion Polymorphisms of the APOBEC3B Gene and HIV-1 Risk

Genetic and mechanistic basis for APOBEC3H alternative splicing, retrovirus restriction, and counteraction by HIV-1 protease

Interaction Between HIV-1 and APOBEC3 Sub-Family of Proteins

The Disassociation of A3G-Related HIV-1 cDNA G-to-A Hypermutation to Viral Infectivity

Conserved and Non-Conserved Features of HIV-1 and SIVagm Vif Mediated Suppression of APOBEC3 Cytidine Deaminases.

Different Mutagenic Potential of HIV-1 Restriction Factors APOBEC3G and APOBEC3F Is Determined by Distinct Single-Stranded DNA Scanning Mechanisms

HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G

Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics

Distinct Determinants In Hiv-1 Vif And Human Apobec3 Proteins Are Required For The Suppression Of Diverse Host Anti-Viral Proteins

Biochemical Characterization of APOBEC3H Variants: Implications for Their HIV-1 Restriction Activity and Mc Modification.